Autologous CD34+ Cell Therapy for Ischemic Tissue Repair

William K. Sietsema, PhD; Atsuhiko Kawamoto, MD, PhD; Hiroshi Takagi, PhD; Douglas W. Losordo, MD

In 1997, the seminal manuscript by Asahara, Murohara, Isner et al outlined the evidence for the existence of circulating, bone marrow-derived cells capable of stimulating and contributing to the formation of new blood vessels. Consistent with the paradigm shift that this work represented, it triggered much scientific debate and controversy, some of which persists 2 decades later. In contrast, the clinical application of autologous CD34 cell therapy has been marked by a track record of consistent safety and clinical benefit in multiple ischemic conditions. In this review, we summarize the preclinical and clinical evidence from over 700 patients in clinical trials of CD34 cell therapy.

Key Words: Cell therapy; Critical limb ischemia; Endothelial progenitor cells; Ischemic tissue repair; Refractory angina

Discovery of CD34 Cells as Endothelial Progenitors

The CD34 cell surface antigen was first identified with monoclonal antibodies targeted to hematopoietic progenitor cells. Early on, CD34+ cells were shown to effectively reconstitute the hematopoietic system of lethally irradiated baboons and rhesus monkeys, providing evidence that CD34+ cells were indeed multipotent stem cells; however, the domain of their effect was thought to be restricted to the hematopoietic system. That all changed in 1997 when Asahara, Murohara, and Isner et al published a groundbreaking report providing evidence that adult human CD34+ cells, well established as hematopoietic stem cells, also harbored the capability to differentiate into endothelial lineage cells. In vitro, CD34+ cells were shown to be null for expression of endothelial markers initially, but under specific culture conditions, typical markers of endothelial lineage were expressed. More notable was the in vivo evidence that human CD34 cells naturally migrated to areas of ischemic injury and preserved or restored microcirculatory integrity. Thus began the age of the endothelial progenitor cell, or EPC, as it is now well known in the cardiovascular lexicon. Subsequent work in multiple laboratories corroborated the existence of EPCs and further elucidated their function (reviewed in Rafi and Werner et al). The most convincing evidence documenting the existence of adult vasculogenesis has come from animal and human studies in the setting of allogeneic bone marrow transplantation, yielding irrefutable genetic verification of vascular endothelium of bone marrow origin.

Natural Human Evidence for the Role of CD34 Cells in Ischemic Repair

With documentation of the EPC contribution to the maintenance of vascular integrity provided by animal and human transplantation studies, a logical question is the role of progenitor cells in the setting of tissue injury and the specific identity of the precursors that effect repair. Shintani et al showed that CD34+ cell counts were significantly increased in patients following myocardial infarction, and Werner et al extended these findings, showing that cardiovascular outcomes in patients following myocardial infarction were improved in patients who mobilized CD34 cells most efficiently. These data suggested that the CD34+ cell was a naturally preprogrammed vascular repair cell, which ignited interest in the potential use of these cells in a therapeutic context.

Preclinical Evidence

Since the original report by Asahara et al, a large number of animal studies investigating the potential therapeutic utility of CD34 cell therapy for ischemic tissue repair have been published (summarized in Tables 1–3) (reviewed in Mackie and Losordo) and we highlight a small percentage of the studies here. These studies document the natural ability of CD34 cells to replenish damaged microvasculature in ischemic tissue (Figure 1).

Hindlimb Ischemia

In 2000, Murohara et al showed that cord blood-derived CD34+ cells augmented perfusion and contributed to neovascularization in a murine hindlimb ischemia model, and the following year Kocher et al documented the...
### Table 1. Preclinical Studies of CD34 Therapy for Ischemic Tissue Repair: Myocardial Infarction

| Reference          | Objective(s)                                                                 | Treatment groups                      | Cell no. | ROA          | Outcomes                                                                 |
|--------------------|------------------------------------------------------------------------------|---------------------------------------|----------|--------------|---------------------------------------------------------------------------|
| Kocher et al.      | Examine effects of GCSF-mobilized human CD34+ cells in a rat model of MI     | CD34+ CD34– Saphenous vein ECs Saline  | 2 x 10⁶  | IV           | Neoangiogenesis in the infarct vascular bed                               |
| Kawamoto et al.    | Investigate whether catheter-based, IMC transplantation of CD34+ cells can enhance neovascularization in MI | CD34+ CD34– PBS                       | 5 x 10⁶  | IMC          | Neovascularization, Myocardial fibrosis, LV function                     |
| Yeh et al.         | Investigate whether CD34+ cells can transdifferentiate into cardiomyocytes, endothelial and/or smooth muscle cells | CD34+                                 | 2.5 x 10⁶ | IV or intraventricular                                                   | Confirmed transdifferentiation of CD34+ cells into cardiomyocytes, mature endothelial cells, and smooth muscle cells in vivo |
| Botta et al.       | Compare CD34+KDR+ cells with CD34+KDR– cells in a mouse model of cardiac ischemia | CD34+ Unseparated MNCs PBS            | 2 x 10⁵  | 2 x 10⁵ IMC | Cardiac function after MI with CD34+ cells, Cardiac hemodynamics with CD34+KDR+ |
| Brenner et al.     | Examine myocardial homing in infarcted and normal hearts                      | Infarcted or sham-operated            | Not reported | Intracavitary-left ventricle    | Homing of CD34+ cells to infarcted tissue with MI CD34+ cells are also found in lung, liver, kidneys, and spleen |
| Ott et al.         | To investigate the therapeutic potential of CD34+ cells in nude rats with MI  | CD34+                                 | 1 x 10⁶  | IMC          | LV function                                                              |
| Yoshioka et al.    | To track the fate of transplanted cells in a model of AMI                     | CD34+ PBS                             | 1.2±0.73 x 10⁶ | IC            | Regional blood flow, Cardiac function                                    |
| Iwasaki et al.     | Examine multilineage capacity of CD34+ cells derived via mobilization and apheresis from human subjects with lower limb ischemia | Low CD34+ Medium CD34+ High CD34+ PBS | 1 x 10⁵  | 1 x 10⁵ IMC | Dose-dependent improvements: Cardiomyocytes in ischemic myocardium, Vasculogenesis |
| Kawamoto et al.    | Compare the therapeutic potential of CD34+ cells with MNCs for the preservation/recovery of myocardial tissue after MI | CD34+ Low-dose MNC High-dose MNC PBS   | 5 x 10⁵  | 5 x 10⁵ IMC | Myocardial integrity, Function                                           |
| Shintani et al.    | Examine the effects of combining human CD34+ cell treatment with local VEGF2 gene therapy in MI | CD34+/empty vector CD34+/VEGF2 CD34+/VEGF2 | Human CD34+ cells; IMC |                              | Fractional shortening, Capillary density, Infarct size                   |
| Zhang et al.       | Examine effect of CD34+ cells in a swine model of MI                          | CD34+ PBS                             | 5 x 10⁷  | ICN          | Cardiac repairs after MI in swine with preexisting coronary collateral vessels |
| Iwasaki et al.     | Examine effect of CD34+ cells on collateral microvessel development          | CD34+ CD34– PBS                       | 1 x 10⁶  | IMC          | Therapeutic benefits in MI                                               |
| Wang et al.        | Determine fate and function of CD34+ cells in SCID mice after experimental MI | CD34+                                 | 1 x 10⁶  | IMC          | Function resulting from angiogenesis and/or paracrine effect, but not myogenesis |
| Mackie et al.      | Explore whether the therapeutic efficacy of CD34+ cells is enhanced with SHH in NOD-SCID mice with MI | Low CD34+ High CD34+ Low CD34+/ empty Low CD34+/SHH Low CD34+/SHH (200 ng) Saline | Low - 2.5 x 10⁴ High - 5 x 10⁴ IMC |                              | Ventricular dilation, Cardiac function decline, Infarct size, Capillary density compared with unmodified CD34+ cells |
| Joladarashi et al. | Determine the role of microRNA on CD34+ cell function in cardiac remodeling | CD34+/miR-377 ctl CD34+/miR-377        | 5 x 10⁴  | IMC          | Silencing of miR-377 resulted in: Angiogenesis, LV remodeling, Cardiac fibrosis |

AMI, acute myocardial infarction; ECs, endothelial cells; IC, intracardiac; ICN, intracoronary; IMC, intramyocardial; IV, intravenous; LV, left ventricular; MI, myocardial infarction; MNCs, mononuclear cells; PBS, phosphate buffered saline; ROA, route of administration; SHH, sonic hedgehog; VEGF, vascular endothelial growth factor.
therapeutic efficacy of human CD34+ cells for treatment of myocardial infarction. Furthermore, treatment with CD34+ cells was able to restore blood flow in diabetic mice with hindlimb ischemia. Labeled CD34+ cells that had been transplanted were observed by histological analysis to have localized to the regenerating muscle.

A more recent study by Kanaya et al evaluated the possible effects of sonic hedgehog (SHH) on the vasculogenic effects of CD34+-derived EPCs. SHH signaling regulates human CD34+ cell fate and function and may potentiate the therapeutic effect of granulocyte colony stimulating factor (GCSF)-mobilized CD34+ cells on ischemic diseases. GCSF-mobilized human peripheral blood CD34+ cells were injected intramuscularly to mice with severe hindlimb ischemia. Blood perfusion recovery, as well as capillary density, was significantly increased with administration of SHH-treated CD34+ cells compared with CD34+ cells alone, suggesting that SHH may be able to enhance the therapeutic potential of CD34+ cells. This corroborates an earlier report by Mackie et al.

The use of subsets of CD34+ cells that are expressing a combination of other endothelial markers has also been examined as a possible therapy for regenerating muscle. It has been shown that the concomitant expression of VEGF-receptor 2 (kinase domain receptor [KDR]) on CD34+ cells improved limb salvage and hemodynamic recovery, and that the neovascularization induced by KDR+ cells was superior to that promoted by KDR− cells.

Taken together, CD34+ cell therapy effectively improves blood perfusion and angiogenesis in models of hindlimb ischemia, and optimization by combination gene therapy or subset selection of CD34+ cells may enhance the recovery response even further.

### Myocardial Infarction
The first evaluation of therapeutic cardiac neovascularization with CD34+ cells used athymic nude rats to show that a single systemic injection of human CD34+ cells after induction of an acute myocardial infarction (AMI) resulted in increased capillary density, increased blood flow because of CD34+ cell-induced angiogenesis and vasculogenesis in the infarct zones. This led to better cardiac function and

---

**Table 2. Preclinical Studies of CD34 Therapy for Repair: Hindlimb Ischemia**

| Reference     | Objective(s)                                                                 | Treatment groups | Cell no.  | ROA   | Outcomes                                           |
|---------------|-------------------------------------------------------------------------------|------------------|-----------|-------|---------------------------------------------------|
| Kanaya et al  | Evaluate the possible effects of SHH on the vasculogenic effects of CD34+ cells in nude mice with HLI | Control CD34+/CD34+/SHH                          | 1×10⁶ IM   | ↑Perfusion ratio with SHH                          |
| Du et al      | Examine the effect of DFO on CD34+ cell targeting and neovascularization in nude mice with HLI | Control CD34+/DFO                                    | 2×10⁴ IA  | ↑Vasculogenesis                                   |
| Matsumura et al | Determine effects of statins on angiogenesis                                      | Atorvastatin Vehicle                                  | – –       | ↑Angiogenic cytokines                              |
| Zhou et al    | Determine therapeutic efficacy of PBMCNs with and without CD34+ cell depletion in HLI | PBMCNs CD34-depleted PBMCNs                          | 1×10⁶ IM   | ↑Capillary density                                |
| Madeddu et al | Examine the angiogenic effects of CD34+KDR+ cells vs. CD34+KDR−cells and placebo in SCID mice with HLI | CD34+/KDR+ 1×10³ | 1×10⁵ IM   | ↑Limb salvage                                      |
| Schatteman et al | Examine the ability of angioblast-containing CD34+ cells to restore blood flow in nondiabetic and diabetic mice with HLI | Vehicle control CD34+CD34− 2.5–5.0×10⁵ IM | ↑Blood flow in diabetic mice compared to nondiabetic mice |

DFO, dexferrioxamine; HLI, hindlimb ischemia; IA, intraarterial; IM, intramuscular; PBMCNs, peripheral blood mononuclear cells. Other abbreviations as in Table 1.

**Table 3. Preclinical Studies of CD34 Therapy for Repair: Cerebral Ischemia/Stroke**

| Reference     | Objective(s)                                                                 | Treatment groups | Cell no.  | ROA   | Outcomes                                           |
|---------------|-------------------------------------------------------------------------------|------------------|-----------|-------|---------------------------------------------------|
| Shyu et al    | Investigate effects of intracerebral administration of PB−CD34+ cells on chronic stroke in Sprague-Dawley rats | CD34+ Vehicle    | 2×10⁵ ICB | ↑Neurological function                            |
| Taguchi et al (2004) | Determine whether CD34+ cells improve neovascularization of cerebral tissue following induction of stroke in SCID mice | Stroke model CD34+/CD34− Saline                     | 5×10⁵ IV   | ↑Neovascularization of the ischemic zone          |

ICB, intracerebral; PB, peripheral blood. Other abbreviations as in Tables 1, 2.
Autologous CD34+ Cell Therapy for Ischemic Disease

CD34+ cells promote angiogenesis of the microvasculature

- CD34+ cells naturally reside in the bone marrow
- Induce capillary growth to regenerate damaged microcirculation

![Figure 1. CD34+ cells promote angiogenesis of the microvasculature.](image)

reduced infarct size, collagen deposition, and apoptosis of cardiomyocytes. The findings were specific to CD34+ cells, because neither the CD34− cell fraction nor fully differentiated endothelial cells was capable of salvaging the infarcted tissue to the same extent.

Kawamoto et al evaluated direct injection of human CD34+ cells into the ischemic zone in a nude-rat model of AMI and evaluated measurable factors associated with cardiac function. Histologically, the results indicated that animals in receipt of CD34+ cells showed a marked increase in capillary density, accompanied by a substantial decrease in the amount of fibrosis associated with the infarct. Histological analysis also revealed that CD34+ cells had integrated into foci of neovascularization located within the peri-infarct zone where they expressed UAE-1 lectin, a marker of mature human endothelial cells, suggestive of differentiation into endothelial cells. This is in agreement with data from Yeh et al, who documented the transdifferentiation of human CD34+ cells into endothelial cells and also revealed that the migration and retention of CD34+ cells into myocardium occurred almost exclusively in the setting of ischemia.

Furthermore, the therapeutic efficacy of mobilized, circulating human CD34+ cells has been compared with that of unselected total mononuclear cell fractions (MNCs) in a rat MI model. Three treatment groups were compared: (1) low-dose selected CD34+ cell group; (2) low-dose MNC cell group; and (3) high-dose MNC group, which contained the same absolute CD34+ cell dose as did group 1. Despite receiving the same absolute number of CD34+ cells, the high-MNC treatment group resulted in increased hemorrhagic MI as evaluated on postsurgical day 3. Tissue staining at that time point indicated an abundance of both hematopoietic and inflammatory cells derived from the xenotransplantation that were not found in the CD34+ cell group, which suggested that the total MNCs were responsible. The CD34+ cell group showed the greatest attenuation of structural changes attributable to the infarct, with the high-dose total MNC group showing an intermediate phenotype when compared with low-dose total MNC or saline treatment.

The conclusions drawn from the studies described agree with those from a nonhuman primate study that also evaluated the therapeutic efficacy of locally injected human CD34+ cells after AMI. Those authors showed that macaques that received intracardiac CD34+ cells showed improvements in regional blood flow and fractional shortening when compared with a saline-treated group.

Cerebral Ischemia/Stroke

Vascularization, such as that induced by CD34+ cells, is necessary for recovery after stroke. Taguchi et al were the first to use CD34+ cells isolated from human umbilical cord blood (hUCB) to treat both young and aged mice subjected to permanent cerebral ischemia induced by ligation of the left middle cerebral artery. Purified CD34+ cells were administered intravenously 48 h after the induction of stroke. Results demonstrated that neovascularization occurred in the treated animals compared with the mice treated with CD34− cells, and that this blood vessel growth was required for endogenous neurogenesis. The induction of neuronal outgrowth after cerebral ischemia requires a supportive network of new vessels, and CD34+ cell therapy demonstrated a crucial role in recovery from cerebral ischemia.

In a separate rat model of chronic stroke, intracerebral injection of CD34+ cells derived from human peripheral blood induced angiogenesis and the injected cells expressed neuronal cell type markers, suggesting that the cells could differentiate to endothelial cells as well as playing an active role in neurogenesis. Functional benefits on neurological behavior were also observed between 14 and 28 days after treatment, including grip strength, body asymmetry, and locomotor activity. Additional applications of CD34+ cell therapy for cerebral ischemia were explored by Tsuji et al in a report that showed beneficial effects of intravenous administration of hUCB-CD34+ cells for neonatal stroke, including improved blood flow to the infarcted area and reduced loss of ipsilateral hemispheric volume.
Clinical Evidence

Following on from the robust preclinical evidence supporting the safety and efficacy of CD34 cells for treatment of ischemic limbs and myocardium, human clinical trials began in an attempt to leverage the innate capabilities of CD34+ cells in the setting of otherwise untreatable ischemic conditions. Here, we highlight the major milestones in the use of CD34 cell therapy in humans. A comprehensive summary of clinical studies performed for the treatment of ischemic tissue repair is presented in Tables 4–6. In all studies CD34 cells were mobilized with GCSF, collected via apheresis and purified using an antibody-coated magnetic bead sorting technique (Figure 2).

Critical Limb Ischemia

Inaba et al were the first to report selection and clinical usage of CD34+ cells from peripheral blood using magnetic separation. Five patients with ischemic limbs caused by atherosclerotic occlusion received intramuscular injections of autologous CD34+ cells, with a mean purity of 40.6%. The reported outcomes include amelioration of pain at 3 days post-injection and increased walking distance 1 week following treatment, benefits that were sustained for over 1 year. This study indicates the utility of peripheral blood-derived CD34+ cells in angiogenesis.

A phase I/IIa clinical trial in 2009 by Kawamoto et al used autologous CD34+ cells to treat patients with CLI caused by peripheral artery disease or Buerger’s disease. The results revealed improved walking distance, which was the primary endpoint, as well as improved pain rating, toe brachial pressure index, transcutaneous partial oxygen pressure, and decreased ulcer size at 12-weeks post-transplantation. A follow-up study reported by Kinoshita et al in 2012 demonstrated a statistically significant improvement in the toe brachial pressure index, transcutaneous partial oxygen pressure, and pain-free walking distance (Trends) (Tables 4–6). In all studies CD34 cells were mobilized with GCSF, collected via apheresis and purified using an antibody-coated magnetic bead sorting technique (Figure 2).

Myocardial Ischemia

Refractory Angina

CD34+ cell therapy has now been evaluated in multiple double-blind, randomized placebo-controlled clinical trials in “no option, refractory, disabling angina” (now referred to as NORDA) patients. An additional study to assess the safety and potential bioactivity of CD34 cell therapy on neovascularization and symptom relief for patients with severe intermittent claudication has demonstrated consistent results.

The first randomized, double-blind, placebo-controlled pilot study was performed in 2012, and followed 28 patients over the course of 12 months. Patients who were not suitable candidates for surgical options received low- or high-dose autologous CD34+ cells or placebo. A favorable and dose-dependent trend was observed in amputation-free survival at 6 months, and this trend was sustained at 12 months post-treatment. Furthermore, no adverse effects were observed after the administration of CD34+ cells.

An additional study to assess the safety and potential bioactivity of CD34 cell therapy on neovascularization and symptom relief for patients with severe intermittent claudication has demonstrated consistent results.

Myocardial Ischemia

Refractory Angina

CD34+ cell therapy has now been evaluated in multiple double-blind, randomized placebo-controlled clinical trials in “no option, refractory, disabling angina” (now referred to as NORDA) patients. The 24 patients with NORDA were enrolled in a randomized, double-blind, placebo-controlled phase 1/2a clinical trial of intramyocardial, autologous, GCSF-mobilized CD34 cell therapy. With the aid of a NOGA™ electromagnetic mapping system, the CD34+ cells were locally injected intramuscularly into the ischemic myocardium. Observations indicated improvements in frequency of angina, use of nitroglycerin, exercise tolerance, and ranking selection and timing, Fujita et al performed a phase II clinical trial that included 11 no-option CLI patients. Results revealed statistically significant improvements in rest pain scales, skin perfusion pressure, transcutaneous partial oxygen pressure, and pain-free walking distance just 2 weeks after treatment. Total walking distance and the toe brachial pressure index were significantly improved at 8 and 12 weeks, respectively. Taken together, these data indicate the safety of the cell therapy, as well as suitable endpoints for no-option CLI patients, and warrant additional later-phase clinical trials.

The first randomized, double-blind, placebo-controlled pilot study was performed in 2012, and followed 28 patients over the course of 12 months. Patients who were not suitable candidates for surgical options received low- or high-dose autologous CD34+ cells or placebo. A favorable and dose-dependent trend was observed in amputation-free survival at 6 months, and this trend was sustained at 12 months post-treatment. Furthermore, no adverse effects were observed after the administration of CD34+ cells.

Table 4. Clinical Studies of CD34 Therapy for Ischemic Tissue Repair: Critical Limb Ischemia

| Reference          | Condition | Patients (n) | Study design                  | ROA            | Cell no.                        | Follow-up (months) | Outcomes                                          |
|--------------------|-----------|--------------|--------------------------------|----------------|---------------------------------|-------------------|--------------------------------------------------|
| Kawamoto et al28    | PAD       | 5            | Single blind, dose escalation trial | IM             | 1x10^6 cells/kg 5x10^6 cells/kg 1x10^6 cells/kg | 36–48             | ↑Toe brachial pressure index                      |
| Kinoshita et al29 (follow-up) | CLI       | 12           |                                 |                |                                 |                   | ↓Pain rating scale                                |
| Losordo et al30     | CLI       | 7            | Randomized, controlled trial    | IM             | Placebo 1x10^6 cells/kg 1x10^6 cells/kg | 6–12              | ↓Walking distance (Trends)                        |
| Fujita et al31      | CLI       | 11           | Open-label, uncontrolled IM     |                | 6.3s5.1x10^7                  | 3–6               | ↓Amputation incidence                             |

CLI, critical limb ischemia; PAD, peripheral artery disease. Other abbreviations as in Tables 1,2.
Autologous CD34+ Cell Therapy for Ischemic Disease

Table 5. Clinical Studies of CD34 Therapy for Ischemic Tissue Repair: Myocardial Ischemia/Infarction, RFA

| Reference            | Condition | Patients (n) | Study design     | ROA       | Cell no.               | Follow-up (months) | Outcomes                                                                 |
|----------------------|-----------|--------------|------------------|-----------|------------------------|--------------------|--------------------------------------------------------------------------|
| Vrtovec et al34      | DCM       | 28           | Randomized, open-label study | IC        | 123±23×10^6           | 12                 | ↓LVEF, ↑Walk test, ↓NT-proBNP, ↑1-year death or heart transplantation   |
| Vrtovec et al35      | DCM       | 20           | Prospective, randomized study | IC        | 103±27×10^6           | 6                  | ↑LVEF, ↑Walk test distance, ↓NT-proBNP in the transcendocardial group compared with intracoronary |
| Vrtovec et al36      | DCM       | 55           | Prospective, randomized study | IC        | 113±26×10^6           | 60                 | ↑LVEF, ↑Walk test, ↓In NT-proBNP, ↓Death                               |
| Lezaic et al37       | DCM       | 21           | Single-arm unblinded study   | IC        | 123±53×10^6 (range 54–284×10^6) | 6                 | ↑Resting myocardial perfusion, ↑LVEF, ↑Walk test                      |
| Musialek et al38     | MI        | 21           | Randomized, controlled study | TC-perfusion | 4.34±10^9 (range 0.92×10^9–7.54×10^9) | <1                | Preferential CD34+ homing in the viable peri-infarct zone              |
| Vrtovec et al39      | STEMI     | 78           | Randomized, controlled study | IA        | Low - 5×10^6         | 6                  | Infarct region perfusion, ↑LVEF (trend), ↓Incidence of decreased LVEF |
| Vrtovec et al (2017)39| STEMI     | 56           | Double-blind, controlled study | IC        | 14.9±8×10^6         | 18 (median)         | Mean LVEF change (dose-dependent), ↓Weekly angina episodes, ↓Nitroglycerine usage |
| Wang et al40         | Intractable angina | 56          | Prospective, double-blind, randomized, phase 2 study | IC        | 5.6±2.3×10^7         | 3–6                | Weekly angina, ↑Myocardial perfusion                                  |
| Losordo et al41      | RFA       | 56           | Randomized, double-blind study | IMC       | Low - 1×10^6 cells/kg High - 5×10^5 cells/kg | 12                | ↑Weekly angina, ↓Exercise tolerance, ↓Death at 12 months             |
| Lee et al42          | CAD       | 18           | Randomized, double-blind study | IC        | Low - 1×10^7 High - 3×10^7 | 9–18.5            | ↑LVEF (both groups), ↑Neovascularization, ↑Angina and heart failure, No deaths |

CAD, coronary artery disease; DCM, dilated cardiomyopathy; LVEF, left ventricular ejection fraction; RFA, refractory angina; TC, transcoronary. Other abbreviations as in Tables 1,2.

on the Canadian Cardiovascular Society (CCS) angina classification scale. This first-in-human study provided initial evidence of safety and bioactivity of this approach and led to a subsequent 167-patient study.

The prospective, double-blind, randomized, phase II ACT34-CMI study enrolled 168 NORDA patients. Subjects treated with an intramyocardial injection of autologous CD34+ cell therapy experienced greater decreases in the frequency of angina, and significant improvements to exercise tolerance after 6 months, which continued to improve at 12 months post-treatment. Further improvements that were observed in the low-dose group compared with controls included: time to onset of angina, nitroglycerine use, and assessment of quality of life and CCS classification. A second year of follow-up was conducted, providing evidence that a single administration of CD34+ cells resulted in reduced angina frequency for at least 2 years, together with a significant reduction in deaths and favorable trends toward reduced major adverse cardiac events. These findings, providing evidence for efficacy and enhanced safety in the severely ill NORDA patient population following intramyocardial injection of GCSF-mobilized autologous CD34+ cell therapy, indicated the need for further development to address the unmet need in this patient population.

The randomized, double-blind, phase III RENEW study provided additional evidence for the improved safety and function in refractory angina patients treated with autologous CD34+ cell therapy. Although this study was terminated prematurely by the sponsor for financial reasons, the data from the partial study are consistent with prior studies showing reduced mortality rates and improved exercise tolerance in treated vs. control subjects.

Myocardial Infarction The PreSERVE-AM1 was the largest clinical trial using CD34 cell therapy for left ventricular (LV) dysfunction post-ST-segment-elevation MI (STEMI). This randomized, double-blind, placebo-controlled phase II trial enrolled 161 patients, of whom 78 received autologous CD34+ cells and 83 received vehicle control treatment by intracoronary infusion. After 12 months, treated subjects experienced 0% mortality vs. 3.6% of the control subjects. In fact, adjusting for total ischemic time resulted in a statistically significant increase in number of days alive and out of hospital when patients received CD34+ cell therapy. Similarly, whereas both the control and cell therapy groups demonstrated similar efficacy after 6 months, an adjustment for total ischemic time revealed a significant association between cell dose and change in exercise tolerance.
patients with a middle cerebral artery infarct. CD34+ cells with 87–97% purity were administered by stereotactic implantation to 15 patients, ≥6 months after stroke onset. The treatment was well tolerated, and treated patients experienced significantly greater improvement in NIHSS, European Stroke Scale (ESS), and the ESS motor subscale compared with the control group 6 to 12 months after treatment.

**Conclusions**

The CD34+ cell is a naturally occurring vascular repair cell. Natural history studies indicate that patients who mobilize CD34+ cells efficiently have improved outcomes after ischemic events, and human sex-mismatched transplant studies provide irrefutable evidence for the contribution of bone marrow in the formation of new endothelium. Preclinical studies in multiple species and ischemic models of cerebral ischemia/infarction have shown promising results, with improved neurological outcomes, reduced infarct size, and increased cerebral blood flow and oxygen consumption rates. However, further clinical trials are needed to establish the efficacy and safety of CD34+ cell therapy for ischemic stroke.

---

**Table 6. Clinical Studies of CD34 Therapy for Ischemic Tissue Repair: Cerebral Ischemia/Stroke**

| Reference | Condition | Patients (n) | Study design | ROA | Cell no. | Follow-up (months) | Outcomes |
|-----------|-----------|--------------|--------------|-----|----------|-------------------|----------|
| Taguchi et al. | Stroke | 6 - Low dose 6 - High dose | Non-randomized, open label | IV | Low: 2.5×10^8 High: 3.4×10^8 (mean) CD34+ 4.4×10^6 | 6 | ↑Neurological outcomes (trend/high dose) ↑Cerebral blood flow ↑O2 consumption rate |
| Banerjee et al. | Stroke | 5 | Non-randomized, open label | IA | 1.2–2.8×10^8 | 6 | ↑Clinical functional scores (modified Rankin Score and NIHSS score) ↓Lesion volume |
| Chen et al. | Middle cerebral artery infarction | 15 | Single-blind, case controlled | IC | 3–8×10^6 | 12 | ↑Stroke scales (NIHSS, ESS, and EMS) ↑Function (modified Rankin Score) ↑Motor-evoked potential response ↓Fiber numbers asymmetry |

EMS, ESS-Motor Subscale; ESS, European Stroke Scale; NIHSS, National Institutes of Health Stroke Scale. Other abbreviations as in Tables 1,2.

---

**Figure 2.** Simple, rapid, scalable and economical CD34 therapy process. GCSF, granulocyte colony stimulating factor.
provide further evidence of the ability of CD34+ cells to stimulate neovascularization and improve perfusion and function is tissues damaged by acute and chronic ischemia.

Most important is the consistent evidence of long-term reversal of ischemic conditions in patients after a single administration of CD34+ cells indicating a regenerative mechanism of action. An ongoing study in Japan, if successful, could lead to the first approval in the world of a cardiovascular regenerative medicine therapy.

**Future Perspectives**

The discovery in 1997 of the CD34+ cell as a naturally occurring microvascular repair cell suggested the attractive possibility that ischemic tissue damage could be repaired, resulting in the attenuation or reversal of declining function. Accumulating clinical evidence has validated this hypothesis. Indeed, these studies have been performed in endstage patients who have exhausted all available therapies and remain disabled with ischemic symptoms. Despite the targeting of these extremely ill patients single administrations of CD34+ cell therapy have generated clear evidence for the reversal of ischemia. Accordingly the evidence supports CD34+ cell therapy as a regenerative medicine.

At present a pivotal trial of CD34+ cell therapy for treatment of critical limb ischemia is underway in Japan. If successfully completed and approved this would represent the first approval in the world of a cardiovascular regenerative medicine.

Once approved it will be important to investigate strategies involving more than a single administration of CD34+ cells to determine if additive benefit can be achieved, as well as exploring other indications in which microvascular repair may be beneficial such as diabetic nephropathy.

**Acknowledgments**

The authors gratefully acknowledge the assistance of Tamar Aprahamian Putri, PhD in the preparation of this manuscript, which was funded by Caladrius Biosciences, Inc., Basking Ridge, NJ, USA.

**Disclosure**

W.K.S., H.T. and D.W.L. are current employees of Caladrius Biosciences, Inc., Basking Ridge, NJ, USA.

**References**

1. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. *J Immunol* 1984; 133: 157–165.
2. Berenson RJ, Andrews RG, Bensinger WI, Kalamasz D, Knitter W.K.S., H.T. and D.W.L. are current employees of Caladrius Biosciences, Inc., Basking Ridge, NJ, USA.
3. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. *J Immunol* 1984; 133: 157–165.
4. Berenson RJ, Andrews RG, Bensinger WI, Kalamasz D, Knitter W.K.S., H.T. and D.W.L. are current employees of Caladrius Biosciences, Inc., Basking Ridge, NJ, USA.
5. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. *J Immunol* 1984; 133: 157–165.
6. Berenson RJ, Andrews RG, Bensinger WI, Kalamasz D, Knitter W.K.S., H.T. and D.W.L. are current employees of Caladrius Biosciences, Inc., Basking Ridge, NJ, USA.
7. Civin CI, Strauss LC, Brovall C, Fackler MJ, Schwartz JF, Shaper JH. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. *J Immunol* 1984; 133: 157–165.
45. Iwasaki H, Kawamoto A, Ishikawa M, Oyamada A, Nakamori
43. Brenner W, Aicher A, Eckey T, Massoudi S, Zuhayra M, Koehl
42. Botta R, Gao E, Stassi G, Bonci D, Pelosi E, Zwas D, et al.
40. Banerjee S, Bentley P, Hamady M, Marley S, Davis J, Shlebak
39. Quyyumi AA, Vasquez A, Kereiakes DJ, Klapholz M, Schaer
36. Henry TD, Schaer GL, Traverse JH, Povisc TJ, Davidson C, Lee
33. Benck L, Henry TD. CD34+ cell therapy for no option refractory
32. Losordo DL, Henry TD, Kibbe MR, Krichavsky M,
31. Losordo DW, Kibbe MR, Mendelsohn F, Marston W, Driver
29. Kinoshita M, Fujita Y, Katayama M, Baba R, Shibakawa M,
1430
992 – 994.
2005; FASEB J
Endothelial-like cells expanded from CD34+ blood cells improve
a rat myocardial infarction model.
45: J Nucl Med
U, et al. 111In-labeled CD34+ hematopoietic progenitor cells in
Heart infarct in NOD-SCID mice: Therapeutic vasculogenesis by
Cell
Intracerebral implantation of autologous peripheral blood stem
acute ischemic stroke.
Circ Res
administration of autologous CD34+ cells in patients with left
double-blind, placebo-controlled clinical trial of intracoronary
Am Heart J
RENEW study.
165: 2013;
administration in patients with refractory angina: Design of the
efficacy and safety of intramyocardial autologous CD34+ cell
transplantation in nonischemic dilated cardiomyopathy patients:
S-year follow-up. Circ Res 2013; 112: 165 – 173.
Lezic L, Socan A, Poglajen G, Lezaic L, Domanovic D, Cernelec P, et al. Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy. J Card Fail 2011; 17: 272 – 281.
9: 1576 – 1585.
319 – 326.
2015; J Card Fail
al. Intracoronary transplantation of CD34(+) cells is associated with improved myocardial perfusion in patients with nonischemic dilated cardiomyopathy. J Card Fail 2015; 21: 145 – 152.
Musilek P, Tekiel L, Kostkiewicz M, Majka M, Szot W, Walter Z, et al. Randomized transcoronary delivery of CD34(+) cells with perfusion versus stop-flow method in patients with recent myocardial infarction: Early cardiac retention of 99mTc-labeled cells activity. J Nucl Cardiol 2011; 18: 104 – 116
Quyyumi AA, Walker EK, Murrow J, Esteses F, Galt J, Oshinski J, et al. CD34+ cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. Am Heart J 2011; 161: 98 – 105.
Wang S, Cui J, Peng W, Lu M. Intracoronary autologous CD34+ stem cell therapy for intractable angina. Cardiology 2010; 117: 140 – 147.
Lee FY, Chen YL, Sung PH, Ma MC, Pei SN, Wu CJ, et al. Intracoronary transfusion of circulation-derived CD34+ cells improves left ventricular function in patients with end-stage diffuse coronary artery disease unsuitable for coronary intervention. Crit Care Med 2015; 43: 2117 – 2132.
Taguchi A, Sakai C, Soma T, Kasahara Y, Stern DM, Kajimoto K, et al. Intravenous autologous bone marrow mononuclear cell transplantation for stroke: Phase 1/2a clinical trial in a homogeneous group of stroke patients. Stem Cells Dev 2015; 24: 2207 – 2218.